Characteristic | level | Overall | Unweighted population | Weighted population (IPTW) | ||||
---|---|---|---|---|---|---|---|---|
Rb group, n (%) | P group, n (%) | p | Rb group, % | P group, % | p | |||
n | 399 | 290 | 109 | |||||
Gender (%) | ||||||||
Female | 170 (42.6) | 116 (40.0) | 54 (49.5) | 0.109 | 42.5 | 47.1 | 0.441 | |
Male | 229 (57.4) | 174 (60.0) | 55 (50.5) | 57.5 | 52.9 | |||
Age | ||||||||
< 60 | 165(41.4) | 194 (66.9) | 71 (65.1) | 0.832 | 68.3 | 62.8 | 0.328 | |
≥ 60 | 134(33.6) | 96 (33.1) | 38 (34.9) | 31.7 | 38.2 | |||
Concurrent chemotherapy regimen (%) | ||||||||
Single | 232 (58.1) | 177 (61.0) | 55 (50.5) | 0.001 | 59.5 | 57.4 | 0.840 | |
Combined | 143 (35.8) | 103 (35.5) | 40 (36.7) | 35.0 | 35.6 | |||
None | 24 (6.0) | 10 (3.4) | 14 (12.8) | 5.4 | 7.0 | |||
Postoperative chemotherapy (%) | ||||||||
no | 107 (26.9) | 70 (24.2) | 37 (33.9) | 0.068 | 27.8 | 32.3 | 0.414 | |
Yes | 291 (73.1) | 219 (75.8) | 72 (66.1) | 72.2 | 67.7 | |||
Radiotherapy strategies (%) | ||||||||
LCRT | 36 (9.0) | 26 (9.0) | 10 (9.2) | < 0.001 | 8.7 | 7.9 | 0.849 | |
LCRT + SIB | 344 (86.2) | 258 (89.0) | 86 (78.9) | 86.5 | 85.8 | |||
SCRT | 19 (4.8) | 6 (2.1) | 13 (11.9) | 4.8 | 6.3 | |||
Number of dissected lymph nodes (%) | ||||||||
< 12 | 195 (48.9) | 151 (52.1) | 44 (40.4) | 0.006 | 49.6 | 46.0 | 0.245 | |
≥ 12 | 195 (48.9) | 136 (46.9) | 59 (54.1) | 49.1 | 49.5 | |||
none | 9 (2.3) | 3 (1.0) | 6 (5.5) | 1.3 | 4.5 | |||
cT (%) | ||||||||
cT1-3 | 158 (41.6) | 122 (44.2) | 36 (34.6) | 0.115 | 44.3 | 34.6 | 0.107 | |
cT4 | 222 (58.4) | 154 (55.8) | 68 (65.4) | 55.7 | 65.4 | |||
cN (%) | ||||||||
cN- | 43 (11.3) | 30 (10.9) | 13 (12.5) | 0.790 | 10.4 | 11.1 | 0.844 | |
cN + | 337 (88.7) | 246 (89.1) | 91 (87.5) | 89.6 | 88.9 | |||
CEA, ng/nl (median [IQR]) | 3.3 [1.9,7.3] | 3.5 [2.0, 7.6] | 3.0 [1.7,6.1] | 0.252 | 3.4 [1.9,7.6] | 2.8 [1.7, 5.8] | 0.191 | |
CA199, U/ml (median [IQR]) | 12.6 [6.9,22.0] | 12.5 [6.6,21.3] | 12.8 [7.9,28.2] | 0.112 | 12.7 [6.6, 21.7] | 11.9 [7.9,25.8] | 0.394 |